Denali Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 445
- Market Cap
- -
- Introduction
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Clinical Trials
41
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
- Conditions
- Parkinson Disease
- Interventions
- Drug: BIIB122 225 mgOther: BIIB122-Matching Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06602193
- Locations
- 🇺🇸
Cedars-Sinai Department of Neurology, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06281158
- Locations
- 🇺🇸
Clinical Site, Madison, Wisconsin, United States
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06181136
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT06075537
- Locations
- 🇺🇸
The University of Texas Medical School at Houston, Houston, Texas, United States
🇮🇹Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia, Udine, Italy
Gazi Universitesi Tip Fakultes, Ankara, Turkey (Türkiye)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05450549
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, South Holland, Netherlands
- Prev
- 1
- 2
- 3
- 4
- Next